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XDiscussion
Dr Ranjit John (Minneapolis, Minn). Members of the Associ-
ation and guests, I appreciate the opportunity to discuss this timely,
important, and well-presented report by Dr Mulloy and his col-
leagues. My conflict of interests include receiving grant support
from Thoratec and HeartWare.
Although heart transplantation and LVADs represent therapeu-
tic options for the same disease, namely heart failure, the applica-
bility of both these treatments differs vastly in terms of their
availability, timing, and acuity of the patients. Although studies
such as these are useful and provide a good reality check on how
our healthcare dollars are being spent, they sometimes ignoreThe Journal of Thoracic and Cathe fact that the LVAD groups are often a much sicker cohort of
patients, who are often in need of immediate therapy.
Furthermore, I believe studies such as these do not consider the
costs in terms of quality of life years, the functional improvements
of LVADs, and, also, importantly, the dramatic effect that, in par-
ticular, the newer generation of LVADs have had on significantly
reducing wait list mortality, now in the very low single-digit range.
Another comment includes that in the current era, the actual
cost of the LVAD, I mean the pump, represents almost 50% of
the overall cost, nearly $100,000. Thus, it is possible, or perhaps
feasible, that with an increased number of these devices and
a more competitive environment, the costs of these devices could
decrease further. I have 3 questions for you.
My first question is whether the results of your study, and you
briefly mentioned it in your discussion, warrant a closer examina-
tion of the guidelines for approving centers to deliver high and ex-
pensive care such as LVADs, especially in view of a trend toward
the increasing availability of LVADs as a therapeutic option?
Dr Mulloy. Regarding your question about the guidelines for
LVAD availability, obviously both of these treatments are incred-
ibly expensive, and, from our standpoint, LVADs are really not
quite ready for a widespread role out in nontransplant hospitals
all over the United States. Our data, and data from others, suggest
that there is still some room for improvement in outcomes and, es-
pecially, in costs. We do not want to advocate, in any sense, a re-
striction of access but just want to ensure that this is done in
a thoughtful and safe way. We do recognize that for centers to be-
come destination therapy centers, there are a number of regulatory
and quality ‘‘hoops to jump through,’’ and I think these regulations
should be embraced as a positive measure toward ensuring that the
dissemination of this new technology is managed safely.
Our specialty, in general, has done avery good jobofpolicingour-
selves through the Society of Thoracic Surgeons and Interagency
Registry for Mechanically Assisted Circulatory Support (INTER-
MACS) databases and the like. I think it is very important to continue
to examine both quality and costs as LVAD therapy is expanded.
There is tremendous pressure to expand this therapy tomany dif-
ferent centers; however, we just urge caution and focus on improv-
ing outcomes and costs before doing that on a widespread level.
Dr John. My second question relates to a study that was pub-
lished last year in the Annals of Thoracic Surgery. Specifically
after Food and Drug Administration approval in a study of almost
1500 HeartMate II LVADs, a significant trend was seen toward
reducing mortality and improving outcomes. Do you believe we
are on the right track toward improving outcomes and thereby
reducing costs or could you outline points that we should be doing
to further reduce costs?
DrMulloy. I definitely agree that as far as improving outcomes,
the study you mentioned and our results both suggest that we are
on that right track. We saw a decrease from 42% to 17% mortality
within just a 4- or 5-year period and to see that on a national level is
almost unprecedented. The outcomes are obviously rapidly im-
proving with Food and Drug Administration approval of the Heart-
Mate II and then with future LVADs coming down the pipeline.
However, I do not think the evidence is there to say that the costs
are also improving. Theoretically, if you have a decrease in compli-
cations and have a shorter hospital stay, the cost of the procedure-
related hospitalization should definitely decrease. However, asrdiovascular Surgery c Volume 145, Number 2 573
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Xpatients live longer, other unforeseen costs will arise, including in-
creased complications, such as bleeding, arrhythmias, and driveline
infections. Thus, I think to say just by improving outcomes we are
going to decrease costs, the evidence just is not there to say that.
Certainly, as you pointed out earlier, the cost of these devices
occupy a huge portion of the total cost of this therapy. Decreasing
the cost of the device would obviously help. I do not think that is
going to happen without some type of external regulatory pressure.
However, as devices improve, with transcutaneous batteries and
elimination of the driveline and smaller devices, the potential def-
initely exists to decrease all those costs.
In summary, the evidence clearly shows that outcomes are im-
proving but the costs of LVADs are not.
Dr John.My final question relates to heart transplantation. For
a therapy that has not changed significantly in terms of its conduct
in the past 20 years, could you speculatewhy the costs increased by
40% during a 4-year period?
Dr Mulloy. That is an excellent question and thank you for
pointing that out. We were surprised to see that. I do need to com-
ment that all these costs are unadjusted costs; that is, we did not
adjust for inflation, mainly because it was such a short period. In-
flation from 2005 to 2009 on the national level was estimated to be
about 8%. Thus, we can state that 8% of that 40%might have been
inflation related.
Probably more important is that a larger number of patients un-
dergoing transplantation have pre-existing LVADs and we are
probably really starting to see that in 2008 and 2009 and also going
forward. I know at our institution, more than 90% of the patients
currently transplanted have a pre-existing LVAD.
Although these LVAD-supported patients might be healthier on
some levels, given their improved end-organ perfusion, transplan-
tation in the setting of a LVAD definitely add some other issues.
There is increased blood product use, which is extremely expen-
sive and carries risk of additional complications. There is defi-
nitely a learning curve associated with transplantation of patients
with a LVAD in place, and I think that might be where some of
that cost increase occurred.
There is 1 figure that I presented in the report but did not have
time for in the presentation in which we showed whether the pa-
tients were discharged routinely to home, home health, a skilled
nursing facility, and so forth. During the 5 years studied, we ob-
served an increase in both discharge with home health and dis-
charge to skilled nursing facilities for transplant patients. Again,
that trend is likely related to the additional issues associated
with transplantation of patients with a pre-existing LVAD and
could explain some of the observed cost increase.
Dr John. Thanks again. Excellent presentation.
Dr Matthias Loebe (Houston, Tex). Thank you very much for
this very important communication. I wonder if you can comment,574 The Journal of Thoracic and Cardiovascular Surgbased on your study, on the fact that both heart transplants and
LVAD implantations are covered by the same diagnosis-related
group and whether it would not make more sense to separate the
2 to have a better idea of the expenses for both heart transplanta-
tions and LVAD implantations, in particular, because, today,
more patients receive LVADs than heart transplants?
DrMulloy. I have to admit, I am a research fellow, and I am not
very familiar with the diagnosis-related group or billing from the
clinical standpoint. Certainly, going forward, we do need to differ-
entiate the costs of these separate therapies and also consider the
sum costs of both, which is something we were unable to do in
the present study. Taking our former Vice-President as an example,
obviously our estimate of $209,000 would incredibly underesti-
mate the total cost directed at a single patient who has received
both an LVAD and a heart transplant. But, sorry, I am unable to ad-
dress your specific diagnosis-related group question.
Dr Kenneth Liao (Minneapolis, Minn). My question is did you
notice any difference between the INTERMACS different levels
and then related with the cost? For example, INTERMACS level
I would cost much more than INTERMACS level III or IV. Can
you comment on that?
Dr Mulloy. That is, unfortunately, something the database pre-
vents us from being able to study. It is definitely a limitation of
a database study, in which we are relying completely on the ‘‘In-
ternational Statistical Classification of Diseases and Related
Health Problems, 9th Revision, Clinical Modification’’ codes to
determine these numbers. That is a very interesting question, but
it is just not something that we were able to study.
Dr Friedhelm Beyersdorf (Freiberg, Germany). I just want to
make a short remark. Terminal heart failure is a huge problem,
concerns the number of patients and the costs for the insurance
companies to treat these patients, and these are costs go into bil-
lions per year. Of the entire sum that has to be spent for terminal
heart failure treatment, less than 5% is in the direction of the sur-
gical treatment. Thus, I just would like to encourage you to de-
velop the surgical treatment still further. The medical treatments
cost so much with rehospitalization and all the other treatments
that, definitely, we can provide good service to our patients,
although for the individual patients, the costs are there, and you
have shown this very clearly. However, it should be seen in com-
parison to the overall costs.
Dr Mulloy. Thank you for making that point. We do not intend
to argue that we should not push forward with LVAD or additional
surgical therapy for heart failure by any means. We just want to
make the point that this should be done thoughtfully, while keep-
ing these costs in mind. We all know that the cost environment in
the United States is changing, with an increased focus on compar-
ative effectiveness, and we just want to bring these concerns to
everyone’s attention as something to think about as we go forward.ery c February 2013
